Open AccessCytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients
Author(s) -
Yousef M. Al-saraireh,
Fatemah O F O Alshammari,
Ahmed M M Youssef,
Sameeh Al-Sarayreh,
Ghadeer Almuhaisen,
Nedal Alnawaiseh,
Jehad Al-Shuneigat,
Hamzeh Mohammad Alrawashdeh
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s332037
Subject(s) - colorectal cancer , medicine , biomarker , metastasis , pathology , differential diagnosis , immunohistochemistry , cancer , disease , oncology , cancer research , biology , biochemistry
Colon cancer is a leading cause of mortality worldwide. It has a relatively poor prognosis; therefore, new therapies are needed. One of the tumour-related enzymes that has gained considerable interest is CYP4Z1. This enzyme has been expressed in many tumours and has been hypothesized as a potential biomarker or target for novel anticancer therapies.